Metacognitive skill training (MCT) for schizophrenic patients

越来越多的人认为，精神分裂症的精神药物治疗需要辅以心理干预，以取得全面的治疗成功。我们的精神分裂症患者元认知训练（MCT）自2006年以来一直由德国研究基金会（DFG）资助（临床试验Mo 969/6-1），它代表了一个有希望的补充标准精神病学治疗的候选对象：先前的研究发现，在积极控制和标准精神药理学治疗改善阳性症状的基础上，具有中等效应大小。dfg资助的MCT试验将使我们能够衡量干预的短期效果（干预后6个月）。然而，现在预测我们的训练对长期的短期影响还为时过早。目前形式的试验可能无法回答MCT是否具有预防作用的问题，因为大多数患者与精神卫生系统保持持续接触，并且在出院后的前6个月内仍然定期服用药物。因此，需要在3年后进行第二次随访，以证明精神分裂症患者在减少复发率和加速精神病理学下降方面将受益于MCT培训。延长试验的要求还将估计重要的次要结果指标，如卫生保健费用。由于MCT有15种语言可供选择，而且其疗效的独立复制也开始出现，延长试验时间将进一步使我们能够在世界范围内建立这种方法。该申请突出了已完成的里程碑，并总结了MCT最近的疗效数据。

There is growing consensus that psychopharmacological treatment in schizophrenia needs to be complemented by psychological interventions in order to achieve comprehensive treatment success. Our metacognitive training for schizophrenia patients (MCT) which has been funded by the German Research Foundation (DFG) since 2006 (clinical trial Mo 969/6-1) represents a promising candidate to complement standard psychiatric care: Prior research has found a medium effect size over and beyond an active control and standard psychopharmacological treatment for the amelioration of positive symptoms. The DFG-funded MCT trial will allow us to measure the short-term efficacy of the intervention (6 months after intervention). However, it would be premature to forecast presumed short-term effects of our training to the long-term. The trial in its current form might not be able to answer the question whether MCT exerts a prophylactic effect since most patients are in sustained contact with the psychiatric health system and still take medication on a regular basis within the first 6 months following discharge. A second follow-up period after 3 years is therefore requested in order to prove that schizophrenia patients will benefit from MCT training in terms of both a reduction of relapse rates and an accelerated decline of psychopathology. The requested prolongation of the trial will also estimate important secondary outcome measures such as health care costs. Since MCT is available in 15 languages and independent replications of its efficacy are beginning to emerge, the trial prolongation would further enable us to establish this approach world-wide. The application highlights the accomplished milestones and also summarizes recent efficacy data of the MCT.